×
About 1,582,210 results

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL
https://www.healio.com/news/hematology-oncology/20200709/lisocabtagene-maraleucel-car-t-shows-durable-response-in-large-bcell-nhl

Jul 9th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

BCMA-targeted CAR-T shows ‘outstanding responses’ in advanced multiple myeloma
https://www.healio.com/hematology-oncology/myeloma/news/online/{bc81f18d-afd1-42ae-89ae-185ee74b50be}/bcma-targeted-car-t-shows-outstanding-responses-in-advanced-multiple-myeloma

May 31st, 2020 - Idecabtagene vicleucel induced responses in nearly three-quarters of patients with relapsed or refractory multiple myeloma, according to initial results of the phase 2 KarMMa trial presented during the ASCO20 Virtual Scientific Program.

CAR-T continues to show durable responses in indolent non-Hodgkin lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{b5b2d115-7000-4df9-8743-26711c3bbde1}/car-t-continues-to-show-durable-responses-in-indolent-non-hodgkin-lymphoma

May 31st, 2020 - Axicabtagene ciloleucel induced a 93% response rate among patients with relapsed or refractory indolent non-Hodgkin lymphoma, according to interim results of the phase 2 ZUMA-5 trial presented during the ASCO20 Virtual Scientific Program.

Pembrolizumab Shows Superior PFS in Relapsed/Refractory Classical Hodgkin Lymphoma
https://www.onclive.com/conference-coverage/asco-2020/pembrolizumab-shows-superior-pfs-in-relapsedrefractory-classical-hodgkin-lymphoma

May 30th, 2020 - Treatment with pembrolizumab (Keytruda) induced a 4.9-month progression-free survival (PFS) benefit over brentuximab vedotin (BV) in patients with relapsed/refractory classical Hodgkin lymphoma, according to findings presented at the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.

Pembrolizumab Doubles 24-Month PFS2 in PD-L1 HNSCC
https://www.onclive.com/conference-coverage/asco-2020/pembrolizumab-doubles-24month-pfs2-in-pdl1-hnscc

May 30th, 2020 - Treatment with pembrolizumab (Keytruda) improved progression-free survival after subsequent therapy (PFS2) for patients with PD-L1–positive, relapsed/refractory head and neck squamous cell carcinoma (HNSCC) compared with the EXTREME regimen, according to an analysis of the KEYNOTE-048 trial. Pembrolizumab induced better PFS2 outcomes both alone and in combination with chemotherapy.

Efficacy of Cabozantinib in Previously Treated RCC Is Consistent Irrespective of Prior Therapy
https://www.targetedonc.com/view/efficacy-of-cabozantinib-in-previously-treated-rcc-is-consistent-irrespective-of-prior-therapy

May 30th, 2020 - A pooled analysis of clinical trial data revealed that systemic therapy with cabozantinib (Cabometyx) in advanced renal cell carcinoma (RCC) induced reliable responses for patients regardless of whether or not they had received prior immunotherapy. Patients from both the phase 3 METEOR (NCT01865747) and the phase 2 Japanese C2001 (NCT03339219) trials comprised the efficacy population whose resu...

CAR T-cell therapy could ‘revolutionize’ treatment of advanced multiple myeloma
https://www.healio.com/hematology-oncology/myeloma/news/online/{808d4883-a0e1-4574-b61d-ec5ce62aa752}/car-t-cell-therapy-could-revolutionize-treatment-of-advanced-multiple-myeloma

May 30th, 2020 - JNJ-4528, a chimeric antigen receptor T-cell therapy, induced early, deep and durable responses among patients with relapsed or refractory multiple myeloma, according to study results presented during the ASCO20 Virtual Scientific Program.

Idecabtagene Vicleucel Highly Active in Heavily Pretreated Myeloma
https://www.onclive.com/conference-coverage/asco-2020/idecabtagene-vicleucel-highly-active-in-heavily-pretreated-myeloma

May 29th, 2020 - The BCMA-targeting CAR T-cell therapy idecabtagene vicleucel (ide-cel; bb2121) induced a response in nearly three-fourths of patients with heavily pretreated relapsed/refractory multiple myeloma, according to topline findings from the pivotal phase 2 KarMMA trial shared during the 2020 ASCO Virtual Scientific Program.

Encouraging Preliminary Findings Demonstrated for Belantamab Mafodotin Combo in R/R Multiple Myeloma
https://www.targetedonc.com/view/encouraging-preliminary-findings-demonstrated-for-belantamab-mafodotin-combo-in-r-r-multiple

May 29th, 2020 - The addition of the antibody-drug conjugate belantamab mafodotin to the standard-of-care doublet of bortezomib (Velcade) and dexamethasone (B-Vd) induced a minimum response of stable disease in all patients treated in a cohort of the phase 1/2 DREAMM-6 trial.

Durable Responses Elicited with Nivolumab Plus Ipilimumab in Advanced NSCLC
https://www.targetedonc.com/view/durable-responses-elicited-with-nivolumab-plus-ipilimumab-in-advanced-nsclc

May 29th, 2020 - Frontline treatment with the combination of with nivolumab (Opdivo) plus ipilimumab (Yervoy) induced durable and long-term efficacy benefits in patients with advanced non-small cell lung cancer (NSCLC) and tumor PD-L1 expression of at least 1% or less than 1%, according to updated results from part 1 of the phase 3 Checkmate 227 trial presented at the 2020 ASCO Virtual Scientific Program.

Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms – An fMRI study
https://www.jns-journal.com/article/S0022-510X(20)30242-2/pdf
Journal of Neurological Sciences;

May 27th, 2020 - Parkinson's disease (PD) patients develop levodopa induced dyskinesia with disease progression from sensitization of central pathways. Pain pathways are also impacted with suggestions dyskinetic patients may process pain differently.

White matter hyperintensities and risk of levodopa‐induced dyskinesia in Parkinson’s disease
https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.50991
Annals of Clinical and Translational Neurology;

Feb 7th, 2020 - To investigate whether the burden of white matter hyperintensities (WMHs) is associated with the risk of developing levodopa‐induced dyskinesia (LID) in Parkinson’s disease (PD).

Blood Flow and Glucose Metabolism Dissociation in the Putamen Is Predictive of Levodopa Induced Dyskinesia in Parkinson's Disease Patients
https://www.frontiersin.org/articles/10.3389/fneur.2019.01217/full
Frontiers in Neurology;

Nov 21st, 2019 - The forefront treatment of Parkinson's disease (PD) is Levodopa. When patients are treated with Levodopa cerebral blood flow is increased while cerebral metabolic rate is decreased in key subcortical regions including the putamen. This phenomenon is especially pronounced in patients with Levodopa-induced dyskinesia (LID).

Levodopa-induced dyskinesia: clinical features, incidence, and risk factors
https://link.springer.com/article/10.1007/s00702-018-1900-6
Neurology and Preclinical Neurological Studies;

Jul 3rd, 2018 - Symptoms of Parkinson’s disease have been controlled with levodopa for many years; however, motor complications consisting of wearing off of medication effect and dyskinesias tend to occur within a few years of starting levodopa. Motor complications can begin a few months after taking levodopa, with the average time to onset estimated to be 6.5 years. Dyskinesias can be troublesome and require ...

COVID-19 revisiting inflammatory pathways of arthritis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304381/
Nature Reviews Rheumatology; Schett G

Jun 19th, 2020 - Coronavirus disease 2019 (COVID-19) is an infectious disease, caused by severe acute respiratory syndrome coronavirus 2, which predominantly affects the lungs and, under certain circumstances, leads to an excessive or uncontrolled immune activation and cytokine response in alveolar structures. The pattern of pro-inflammatory cytokines induced in COVID-19 has similarities to those targeted in th...

Pooled Analysis of Phase 3 studies of ADS-5102 (amantadine hydrochloride) extended release capsules for Levodopa-Induced Dyskinesia: A detailed review of UDysRS Results (S56.003)
https://n.neurology.org/content/88/16_Supplement/S56.003
Neurology

Apr 17th, 2017 - Data from two Phase 3 clinical studies investigating the efficacy and safety of ADS-5102 in Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID) were pooled to summarize results for the shared primary endpoint, Unified Dyskinesia Rating Scale (UDysRS) and its sub-components.

Ocular changes in patients with psoriasis
https://www.sciencedirect.com/science/article/abs/pii/S0738081X19301403?via=ihub
Clinics in Dermatology; Demerdjieva Z

Dec 1st, 2019 - Eye involvement in psoriasis is little known to many dermatologists, although psoriasis has been acknowledged as a systemic disease for decades. The ophthalmic complications of psoriasis are numerous and can affect almost any part of the eye. The most common ocular changes in patients with psoriasis, including blepharitis, conjunctivitis, keratitis, iridocyclitis, UV-induced cataracts, uveitis,...

Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications
https://www.frontiersin.org/articles/10.3389/fneur.2014.00242/full
Frontiers in Neurology;

Dec 15th, 2014 - The dopamine (DA) precursor l-DOPA has been the most effective treatment for Parkinson’s disease (PD) for over 40 years. However, the response to this treatment changes with disease progression, and most patients develop dyskinesias (abnormal involuntary movements) and motor fluctuations within a few years of l-DOPA therapy.

Metabotropic Glutamate Receptors for Parkinson's Disease Therapy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703788/
Parkinson's Disease;

May 29th, 2013 - Excessive glutamatergic signalling within the basal ganglia is implicated in the progression of Parkinson's disease (PD) and inthe emergence of dyskinesia associated with long-term treatment with L-DOPA. There is considerable research focus on the discovery and development of compounds that modulate glutamatergic signalling via glutamate receptors, as treatments for PD and L-DOPA-induced dyskin...

Advances in understanding l-DOPA-induced dyskinesia
https://www.sciencedirect.com/science/article/abs/pii/S0959438808000068?via=ihub
Current Opinion in Neurobiology;

Mar 4th, 2008 - The crucial role of dopamine (DA) in movement control is illustrated by the spectrum of motor disorders caused by either a deficiency or a hyperactivity of dopaminergic transmission in the basal ganglia. The degeneration of nigrostriatal DA neurons in Parkinson's disease causes poverty and slowness of movement. These symptoms are greatly improved by pharmacological DA replacement with l-3,4-dih...